EA199900494A1 - Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола - Google Patents

Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола

Info

Publication number
EA199900494A1
EA199900494A1 EA199900494A EA199900494A EA199900494A1 EA 199900494 A1 EA199900494 A1 EA 199900494A1 EA 199900494 A EA199900494 A EA 199900494A EA 199900494 A EA199900494 A EA 199900494A EA 199900494 A1 EA199900494 A1 EA 199900494A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diola
purin
tetrahydrofuran
derivatives
therapy
Prior art date
Application number
EA199900494A
Other languages
English (en)
Other versions
EA001714B1 (ru
Inventor
Брайан Кокс
Сюзанн Элейн Килинг
Дейвид Джордж Аллен
Элисон Джудит Редгрейв
Майкл Дейвид Баркер
Хизер Хоббс
Томас Дейвис Ропер IV
Джоанна Виктория Гиден
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626852.9A external-priority patent/GB9626852D0/en
Priority claimed from GBGB9626846.1A external-priority patent/GB9626846D0/en
Priority claimed from GBGB9626845.3A external-priority patent/GB9626845D0/en
Priority claimed from GBGB9720536.3A external-priority patent/GB9720536D0/en
Priority claimed from GBGB9722730.0A external-priority patent/GB9722730D0/en
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA199900494A1 publication Critical patent/EA199900494A1/ru
Publication of EA001714B1 publication Critical patent/EA001714B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

Согласно изобретению предложены новые соединения формулы (I), где R, Rи Rтакие, как описано в описании изобретения, способы их получения, содержащие их препараты и их применение в терапии для лечения воспалительных заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900494A 1996-12-24 1997-12-22 Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола EA001714B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9626852.9A GB9626852D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9626846.1A GB9626846D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9626845.3A GB9626845D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9720536.3A GB9720536D0 (en) 1997-09-27 1997-09-27 Chemical compounds
GBGB9722730.0A GB9722730D0 (en) 1997-10-29 1997-10-29 Chemical compounds
PCT/EP1997/007197 WO1998028319A1 (en) 1996-12-24 1997-12-22 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Publications (2)

Publication Number Publication Date
EA199900494A1 true EA199900494A1 (ru) 2000-02-28
EA001714B1 EA001714B1 (ru) 2001-08-27

Family

ID=27517393

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900494A EA001714B1 (ru) 1996-12-24 1997-12-22 Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола

Country Status (36)

Country Link
US (2) US6426337B1 (ru)
EP (1) EP0948509B1 (ru)
JP (1) JP4156035B2 (ru)
KR (1) KR20000069682A (ru)
CN (1) CN1246124A (ru)
AP (1) AP1105A (ru)
AR (1) AR011044A1 (ru)
AT (1) ATE226212T1 (ru)
AU (1) AU733684B2 (ru)
BG (1) BG63310B1 (ru)
BR (1) BR9714082A (ru)
CA (1) CA2275271A1 (ru)
CO (1) CO4940488A1 (ru)
CZ (1) CZ230999A3 (ru)
DE (1) DE69716468T2 (ru)
DK (1) DK0948509T3 (ru)
EA (1) EA001714B1 (ru)
EE (1) EE04019B1 (ru)
ES (1) ES2186015T3 (ru)
GE (1) GEP20022656B (ru)
HU (1) HUP0000673A3 (ru)
ID (1) ID22271A (ru)
IL (1) IL130547A0 (ru)
IS (1) IS5089A (ru)
NO (1) NO312840B1 (ru)
NZ (1) NZ336332A (ru)
OA (1) OA11071A (ru)
PE (1) PE27499A1 (ru)
PL (1) PL334218A1 (ru)
PT (1) PT948509E (ru)
SI (1) SI0948509T1 (ru)
SK (1) SK86599A3 (ru)
TR (1) TR199901905T2 (ru)
TW (1) TW528755B (ru)
WO (1) WO1998028319A1 (ru)
YU (1) YU29099A (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ATE246701T1 (de) * 1998-06-23 2003-08-15 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9930082D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
AU2002238748A1 (en) * 2001-03-12 2002-09-24 Glaxo Group Limited Pharmaceutical aerosol formulation
JP2002338593A (ja) * 2001-05-22 2002-11-27 Ajinomoto Co Inc β−Ｄ−リボフラノース誘導体又はその光学異性体の製造方法
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
EP2221307A1 (en) * 2004-05-26 2010-08-25 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
ATE531377T1 (de) * 2004-09-20 2011-11-15 Inotek Pharmaceuticals Corp Purin-derivate und anwendungsverfahren
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
CN101321460A (zh) * 2005-11-30 2008-12-10 伊诺泰克制药公司 嘌呤衍生物及其用法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010123931A1 (en) * 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PT2467141T (pt) 2009-08-17 2019-02-06 Intellikine Llc Compostos heterocíclicos e suas utilizações
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
EP2509606A1 (en) * 2009-12-09 2012-10-17 Glaxo Group Limited Novel medical use
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
AU2012205791B2 (en) * 2011-01-10 2016-11-03 Invion, Ltd. Use of beta-adrenergic inverse agonists for smoking cessation
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
DK2807178T3 (en) 2012-01-26 2017-09-04 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2R, 3S, 4R, 5R) -5- (6- (cyclopentylamino) -9H-purin-9-yl) -3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes for their preparation
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
CN110818660B (zh) * 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
SG11202012001YA (en) 2018-06-21 2021-01-28 Calithera Biosciences Inc Ectonucleotidase inhibitors and methods of use thereof
KR20220024629A (ko) * 2019-06-20 2022-03-03 칼리테라 바이오사이언시즈, 인코포레이티드 엑토뉴클레오티다제 억제제 및 이의 사용 방법
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3796700A (en) 1970-06-30 1974-03-12 Takedo Chem Ind Ltd Adenosine derivatives and the production thereof
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) * 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
AU582359B2 (en) 1984-04-18 1989-03-23 Nelson Research & Development Company N-6 substituted adenosine derivatives as cardiac vasodilators
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
FI880405A (fi) 1987-02-04 1988-08-05 Ciba Geigy Ag Adenosin-5'-karboxamidderivat.
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US5506347A (en) 1993-02-03 1996-04-09 Gensia, Inc. Lyxofuranosyl analogues of adenosine
EP0423777A3 (en) 1989-10-19 1991-09-25 G.D. Searle & Co. Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
EP0550631B1 (en) 1990-09-25 1997-01-02 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994002497A1 (en) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
DE69428536T2 (de) 1993-07-13 2002-06-06 Nasa A3 -adenosin -rezeptor agonisten
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
BG103518A (en) 2000-01-31
KR20000069682A (ko) 2000-11-25
TW528755B (en) 2003-04-21
BG63310B1 (bg) 2001-09-28
US6426337B1 (en) 2002-07-30
SI0948509T1 (en) 2003-06-30
PE27499A1 (es) 1999-03-30
CZ230999A3 (cs) 1999-12-15
WO1998028319A1 (en) 1998-07-02
US6528494B2 (en) 2003-03-04
NZ336332A (en) 2000-12-22
US20020086850A1 (en) 2002-07-04
EP0948509B1 (en) 2002-10-16
AP9901572A0 (en) 1999-06-30
JP2001506668A (ja) 2001-05-22
OA11071A (en) 2002-11-18
NO993114D0 (no) 1999-06-23
DE69716468D1 (de) 2002-11-21
JP4156035B2 (ja) 2008-09-24
PL334218A1 (en) 2000-02-14
ES2186015T3 (es) 2003-05-01
HUP0000673A3 (en) 2003-01-28
CA2275271A1 (en) 1998-07-02
EE9900312A (et) 2000-02-15
AU733684B2 (en) 2001-05-24
NO993114L (no) 1999-08-23
DK0948509T3 (da) 2003-02-24
GEP20022656B (en) 2002-03-25
HUP0000673A2 (hu) 2001-06-28
AU5762298A (en) 1998-07-17
EP0948509A1 (en) 1999-10-13
DE69716468T2 (de) 2003-05-28
EA001714B1 (ru) 2001-08-27
AR011044A1 (es) 2000-08-02
ID22271A (id) 1999-09-23
YU29099A (sh) 2002-06-19
ATE226212T1 (de) 2002-11-15
IL130547A0 (en) 2000-06-01
CN1246124A (zh) 2000-03-01
BR9714082A (pt) 2000-05-09
IS5089A (is) 1999-06-22
NO312840B1 (no) 2002-07-08
AP1105A (en) 2002-09-04
CO4940488A1 (es) 2000-07-24
SK86599A3 (en) 2000-05-16
PT948509E (pt) 2003-03-31
TR199901905T2 (xx) 1999-10-21
EE04019B1 (et) 2003-04-15

Similar Documents

Publication Publication Date Title
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
EA199901063A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200100127A1 (ru) Производные фенилксантина
EA199900620A1 (ru) Фталазиноны
EA199800667A1 (ru) Новые фенантридины
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
ATE253586T1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
EE03869B1 (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
EA200201214A1 (ru) Замещенные тиоацетамиды
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
DK0471756T3 (da) Saccharinderivater, der er egnede som proteolytiske enzyminhibitorer, og fremstilling deraf

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ KG MD TM RU